AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.13M | 35.32M | 32.88M | 23.12M | 28.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.13M | 35.32M | 32.88M | 23.12M | 28.83M |
| Cost of Revenue | 186.83M | 182.81M | 168.75M | 170.47M | 167.26M |
| Gross Profit | -111.70M | -147.49M | -135.88M | -147.35M | -138.43M |
| SG&A Expenses | 83.23M | 85.18M | 82.50M | 83.84M | 85.49M |
| Depreciation & Amortization | 22.17M | -3.39M | 28.29M | 59.34M | 58.85M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 292.23M | 264.60M | 279.54M | 313.65M | 311.60M |
| Operating Income | -217.11M | -229.28M | -246.66M | -290.53M | -282.77M |
| Income Before Tax | -177.60M | -204.93M | -198.79M | -210.63M | -200.40M |
| Income Tax Expenses | -31.18M | -33.25M | -33.12M | -42.76M | -37.54M |
| Earnings from Continuing Operations | -146.41 | -171.68 | -165.67 | -167.87 | -162.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.41M | -171.68M | -165.67M | -167.87M | -162.86M |
| EBIT | -217.11M | -229.28M | -246.66M | -290.53M | -282.77M |
| EBITDA | -194.93M | -198.52M | -184.23M | -197.05M | -189.77M |
| EPS Basic | -0.49 | -0.58 | -0.56 | -0.57 | -0.55 |
| Normalized Basic EPS | -0.37 | -0.40 | -0.42 | -0.45 | -0.43 |
| EPS Diluted | -0.49 | -0.58 | -0.56 | -0.57 | -0.56 |
| Normalized Diluted EPS | -0.37 | -0.40 | -0.42 | -0.45 | -0.43 |
| Average Basic Shares Outstanding | 1.19B | 1.19B | 1.19B | 1.18B | 1.18B |
| Average Diluted Shares Outstanding | 1.19B | 1.19B | 1.19B | 1.18B | 1.18B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |